A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial.

Journal of Neuromuscular Diseases
Richard S Finkel(For the PolarisDMD Study Group)

Abstract

Edasalonexent (CAT-1004) is an orally-administered novel small molecule drug designed to inhibit NF-κB and potentially reduce inflammation and fibrosis to improve muscle function and thereby slow disease progression and muscle decline in Duchenne muscular dystrophy (DMD). This international, randomized 2 : 1, placebo-controlled, phase 3 study in patients ≥4 - < 8 years old with DMD due to any dystrophin mutation examined the effect of edasalonexent (100 mg/kg/day) compared to placebo over 52 weeks. Endpoints were changes in the North Star Ambulatory Assessment (NSAA; primary) and timed function tests (TFTs; secondary). Assessment of health-related function used the Pediatric Outcomes Data Collection tool (PODCI). One hundred thirty one patients received edasalonexent (n = 88) and placebo (n = 43). At week 52, differences between edasalonexent and placebo for NSAA total score and TFTs were not statistically significant, although there were consistently less functional declines in the edasalonexent group. A pre-specified analysis by age demonstrated that younger patients (≤6.0 years) showed more robust and statistically significant differences between edasalonexent and placebo for some assessments. Treatment was well-tolerated an...Continue Reading

References

Aug 12, 1994·Science·E Kopp, S Ghosh
Mar 13, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ashok Kumar, Aladin M Boriek
Nov 3, 2006·The Journal of Clinical Investigation·Foteini MourkiotiNadia Rosenthal
Mar 24, 2007·The Journal of Clinical Investigation·Swarnali AcharyyaDenis C Guttridge
Jun 25, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Hong LiAshok Kumar
Dec 15, 2010·Pediatrics·Hugh J McMillanPeter B Kang
Mar 18, 2011·Developmental Medicine and Child Neurology·Anna MayhewUNKNOWN North Star Clinical Network for Paediatric Neuromuscular Disease
May 31, 2011·Current Topics in Developmental Biology·Jennifer M PetersonDenis C Guttridge
Sep 29, 2011·Physiotherapy Research International : the Journal for Researchers and Clinicians in Physical Therapy·Elaine ScottUNKNOWN North Star Clinical Network for Paediatric Neuromuscular Disease
Mar 12, 2013·International Journal of Language & Communication Disorders·Sally K ArcherSimon Miller
May 15, 2013·The International Journal of Biochemistry & Cell Biology·Jonghyun ShinAshok Kumar
Jul 24, 2013·Annals of Physical and Rehabilitation Medicine·P KienyB Perrouin Verbe
Aug 6, 2013·Developmental Medicine and Child Neurology·Anna G MayhewUNKNOWN North Star Clinical Network for Neuromuscular Disease
May 2, 2014·Neuromuscular Disorders : NMD·Jean K MahNathalie Jette
Aug 8, 2015·Science Translational Medicine·Amy S RosenbergJanet Woodcock
Jan 20, 2016·Journal of Medicinal Chemistry·Chi B VuMichael R Jirousek
Feb 13, 2016·Journal of Neuromuscular Diseases·Erik LandfeldtKatharine Bushby
Oct 21, 2019·Neuromuscular Disorders : NMD·Giorgia CorattiEugenio Mercuri

❮ Previous
Next ❯

Citations

Nov 19, 2021·Frontiers in Pharmacology·Theodora MarkatiLaurent Servais

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here